154 related articles for article (PubMed ID: 18685792)
21. The use of optical techniques to detect conformational changes associated with the interaction of epidermal growth factor and its receptor.
Waterfield MD; Greenfield C; Hiles I; Federwisch M; Wollmer A; Blundell TL; McDonald N
Adv Second Messenger Phosphoprotein Res; 1990; 24():301-6. PubMed ID: 2119642
[No Abstract] [Full Text] [Related]
22. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells.
Perez-Torres M; Valle BL; Maihle NJ; Negron-Vega L; Nieves-Alicea R; Cora EM
Exp Cell Res; 2008 Oct; 314(16):2907-18. PubMed ID: 18687326
[TBL] [Abstract][Full Text] [Related]
23. Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of living cells.
Kozer N; Henderson C; Jackson JT; Nice EC; Burgess AW; Clayton AH
Phys Biol; 2011 Dec; 8(6):066002. PubMed ID: 21946082
[TBL] [Abstract][Full Text] [Related]
24. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos.
Zhao C; Du G; Skowronek K; Frohman MA; Bar-Sagi D
Nat Cell Biol; 2007 Jun; 9(6):706-12. PubMed ID: 17486115
[TBL] [Abstract][Full Text] [Related]
25. S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity.
Murillo-Carretero M; Torroglosa A; Castro C; Villalobo A; Estrada C
Free Radic Biol Med; 2009 Feb; 46(4):471-9. PubMed ID: 19056486
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor dimerization monitored in live cells.
Blakely BT; Rossi FM; Tillotson B; Palmer M; Estelles A; Blau HM
Nat Biotechnol; 2000 Feb; 18(2):218-22. PubMed ID: 10657132
[TBL] [Abstract][Full Text] [Related]
27. Predominance of activated EGFR higher-order oligomers on the cell surface.
Clayton AH; Orchard SG; Nice EC; Posner RG; Burgess AW
Growth Factors; 2008 Dec; 26(6):316-24. PubMed ID: 18937111
[TBL] [Abstract][Full Text] [Related]
28. The bioactivity and receptor affinity of recombinant tagged EGF designed for tissue engineering applications is defined by the nature and position of the tags.
Boucher C; St-Laurent G; Loignon M; Jolicoeur M; De Crescenzo G; Durocher Y
Tissue Eng Part A; 2008 Dec; 14(12):2069-77. PubMed ID: 18652537
[TBL] [Abstract][Full Text] [Related]
29. Green fluorescent protein as a tool to study epidermal growth factor receptor function.
Hayes N; Howard-Cofield E; Gullick W
Cancer Lett; 2004 Apr; 206(2):129-35. PubMed ID: 15013518
[TBL] [Abstract][Full Text] [Related]
30. Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.
Lu JX; Peng Y; Meng ZF; Jin LQ; Lu YS; Guan MX
Biochem Biophys Res Commun; 2005 Aug; 334(1):157-61. PubMed ID: 15993840
[TBL] [Abstract][Full Text] [Related]
31. Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer.
Boute N; Pernet K; Issad T
Mol Pharmacol; 2001 Oct; 60(4):640-5. PubMed ID: 11562424
[TBL] [Abstract][Full Text] [Related]
32. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
33. [Cytoskeletal changes in A-431 cells under the action of epidermal growth factor].
Skopicheva VI; Skopichev VG; Vinogradova NA; Teslenko LV; Nikol'skiĭ NN
Tsitologiia; 1991; 33(4):60-4. PubMed ID: 1725073
[TBL] [Abstract][Full Text] [Related]
34. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
35. Receptor overexpression or inhibition alters cell surface dynamics of EGF-EGFR interaction: new insights from real-time single molecule analysis.
Yu C; Hale J; Ritchie K; Prasad NK; Irudayaraj J
Biochem Biophys Res Commun; 2009 Jan; 378(3):376-82. PubMed ID: 19014905
[TBL] [Abstract][Full Text] [Related]
36. Compartmentalization of epidermal growth factor receptor in liver plasma membrane.
Wang Y; Posner BI; Balbis A
J Cell Biochem; 2009 May; 107(1):96-103. PubMed ID: 19288512
[TBL] [Abstract][Full Text] [Related]
37. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
[TBL] [Abstract][Full Text] [Related]
38. The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor.
Boran AD
Biochem Soc Trans; 2012 Feb; 40(1):195-9. PubMed ID: 22260689
[TBL] [Abstract][Full Text] [Related]
39. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.
Lee DH; Szczepanski MJ; Lee YJ
J Cell Biochem; 2009 Apr; 106(6):1113-22. PubMed ID: 19229860
[TBL] [Abstract][Full Text] [Related]
40. Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain.
Vernet E; Lundberg E; Friedman M; Rigamonti N; Klausing S; Nygren PA; Gräslund T
N Biotechnol; 2009 Sep; 25(6):417-23. PubMed ID: 19552886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]